Chair, Percheron Therapeutics

Dr Charmaine Gittleson

Role	Organisation	Sources
Chair	Percheron Therapeutics	Biotech Dispatch (1 Sep 2026), Biotech Dispatch (10 Aug 2026)

Coverage

Stories naming Dr Charmaine Gittleson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Unnamed stage $2.3m

Percheron raises $2.3 million to fully fund Vanderbilt AML trial

Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.

Biotech Dispatch 1 Sep 2026 Percheron Therapeutics Blue Ocean Equities Cygnet Capital Dr Charmaine Gittleson Dr Michael Baker

Key hire

Percheron turns to former Arovella chief Michael Baker for next phase of HMBD-002 development

Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.

Biotech Dispatch 10 Aug 2026 Arovella Therapeutics BioScience Managers La Trobe University Melbourne Business School Percheron Therapeutics Radiopharm Theranostics Dr Charmaine Gittleson Dr James Garner Dr Michael Baker

Something wrong? Tell us

Dr Charmaine Gittleson

Roles

Coverage

Percheron raises $2.3 million to fully fund Vanderbilt AML trial

Percheron turns to former Arovella chief Michael Baker for next phase of HMBD-002 development